India’s National Institute of Pharmaceutical Education and Research (NIPER) located at Mohali, in the northern state of Punjab, has been able to manufacture raw material for generating nanocrystal-based medicines. The U.S. and Ireland are other countries where this capability exists.
NIPER has obtained an Indian patent for the technology and has applied for the U.S. and the European patents. The technology will cut the cost of such drugs by almost half, claim experts who have developed the technology in NIPER, reports The Times of India. NIPER’s process still remains in lab trials, but the institution has entered a development and commercialization agreement with Indian Windlas Biotech.
Dr. K. K. Bhutani acting director of NIPER said, “Unlike the available and patented technology abroad, the indigenous process generates nanocrystals directly as a solid powder, rather than as a nano-suspension in liquid that has to be subsequently converted into a solid. This has helped in cutting down the cost of generating nanocrystal raw material and opening further competition in the pharmaceutical drug development market.”
Last updated: December 26th, 2025
